After two years of controversy over the cost of hepatitis C treatments, the fast-growing market is poised to undergo a price war.
Late Thursday, Merck received Food and Drug Administration approval for its Zepatier medication and set a list price of just $54,600 for a 12-week course of treatment. This is considerably lower than the cost of rival medicines that have helped spark national outrage over prescription drug pricing.
Will it work on type 3 Hep c
Comments are closed.